MBRX Moleculin Biotech, Inc.: institutional ownership and insider trading
18 funds reported holding $570K of Moleculin Biotech, Inc. in their latest 13F filings; in Q2 2026 funds net bought $93.9K, with 5 new positions and 7 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market; over its last four quarters it reported revenue of $0 and net income of $36.8M.
MBRX revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income −$7.64M
- Quarter ended Mar 31, 2026: revenue $0, net income −$12.8M
- Quarter ended Dec 31, 2025: revenue $0, net income $82.7M
- Quarter ended Sep 30, 2025: revenue $0, net income −$25.4M
Largest institutional holders of MBRX
- GEODE CAPITAL MANAGEMENT, LLC — $132K
- VANGUARD CAPITAL MANAGEMENT LLC — $118K
- VANGUARD FIDUCIARY TRUST CO — $83.4K
- XTX Topco Ltd — $64.0K
- MORGAN STANLEY (MS, MS-PA, MS-PE, MS-PF, MS-PI, MS-PK, MS-PL, MS-PO, MS-PP, MS-PQ) — $55.9K
- VANGUARD GROUP INC — $51.5K
- Rockefeller Capital Management L.P. — $41.9K
- Tower Research Capital LLC (TRC) — $9.80K
- CITIGROUP INC (C, C-PN) — $7.46K
- BARCLAYS PLC (BCS, BCLYF) — $1.73K
Recent MBRX insider trades
- Aug 3, 2026: Foster Jonathan P. bought 293,333 shares ($0)
- Aug 3, 2026: Klemp Walter V bought 533,333 shares ($0)
- Aug 3, 2026: Picker Donald H bought 173,333 shares ($0)
- Jun 23, 2025: Foster Jonathan P. bought 270,270 shares ($100K)
5%+ owners
- CVI Investments, Inc.: 9.9% (Schedule 13G, filed Aug 10, 2026)
- KLEMP WALTER V: 9.9% (Schedule 13D, filed Aug 25, 2026)
- Foster Jonathan P.: 6.3% (Schedule 13D, filed Aug 25, 2026)